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Calpains are ubiquitous intracellular calcium- and thiol-dependent proteases. Their over activation,
resulting in the degradation of various substrates, has been implicated in a number of cardiovascu-
lar and neurological disorders. Here, we present the ﬁrst structural characterization of LSEAL penta-
peptide, a potent calpain inhibitor, bound to the calmodulin-like domain of calpain. Our in vitro
binding data supports the idea that domains other than calpain’s active site may be suitable targets
for future development of therapeutic agents to be used to treat heart attack, traumatic brain inju-
ries or a variety of neurodegenerative conditions, such as ischemic stroke.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Calpains are a family of intracellular Ca2+-dependent cysteine
proteases that are widely expressed with both ubiquitous and tis-
sue-speciﬁc isoforms [1]. These enzymes exist as heterodimers and
are typically composed of an 80 kDa catalytic and a 30 kDa regula-
tory subunits (Fig. 1A). For maximal activity, these proteases re-
quire both calcium and a reducing environment [2] as well as the
presence of both subunits. In addition to these characteristics, cal-
pain is also unique in the nature of its substrate cleavage pattern
and recognition. Calpain cleavage usually results in the processing
of a protein whereby large enzymatically active domains of sub-
strate remain intact, suggesting that calpain cleavage events play
a modulatory role in biological processes [1]. In addition, cleavage
sites are not easily predicted as the primary amino acid sequence
at the cleavage site is not conserved. Rather, it seems that calpain
recognizes a conformation which may or may not be located near
the cleavage site [3]. With increasing evidence for calpain’s role in
cytoskeletal disruption and cell death [4] observed in ischemiachemical Societies. Published by E
py; NOESY, nuclear Overha-
le quantum correlation; L–J,
. Vinogradova); +1 859 257
ttmann), olga.vinogradova@models, the development of calpain inhibitors becomes an impor-
tant objective. Unfortunately, calpain inhibitors presently available
are not speciﬁc and affect other thiol-proteases such as the caspas-
es and cathepsins [5]. In addition, because current compounds re-
act with the thiol moiety of the active site cysteine, these
compounds may not be as effective as predicted under the condi-
tions of oxidative stress where cysteines are oxidized. Therefore,
development of cell permeable, highly soluble, stable, potent and
speciﬁc calpain inhibitors is necessary.
It is known that calpains become active in the presence of cal-
cium due to conformational changes induced by calcium binding
to the EF hand motif in the C-terminus of both the large and the
small subunits [6]. The binding of calcium results in a change of
conﬁguration that exposes the cysteine in calpain’s active site to
substrate. This allows for the catalytic triad (Cys-His-Asn) to be
properly aligned and for peptide bond cleavage to occur. However,
it has also been shown that bovine calpain irreversibly inactivated
with Z-LLY-CHN2 still binds its natural substrate casein [3]. One
possibility to explain this phenomenon is the existence of an addi-
tional calcium-dependent substrate binding modulatory site with-
in the calpain protein which is different from the cleavage site,
suggesting that domains other than calpain’s active site (domain
II in Fig. 1A) may be suitable targets for regulatory action by phar-
macological agents. We have previously identiﬁed a number of
penta-peptides with highly speciﬁc Ca2+-dependent afﬁnity to
calpain [7] using phage-display based technology and demon-
strated that the synthetic LSEAL peptide inhibited calpain I and IIlsevier B.V. All rights reserved.
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Fig. 1. (A) Schematic domain representation of calpain: domains I to IV compose
large and domains V and VI – small subunits. Protease activity is localized to
domain II, domains IV and VI are the calcium binding segments that are implicated
in activation and regulation of the enzyme. Five potential Ca2+ binding EF-hands in
each subunit are represented as stars. Four bind Ca2+ and the ﬁfth embraces one
another to create the heterodimer interface [10]. (B) Repeat domain structure of
human calpastatin. Regions A (20 residues), B (26) and C (20) are highly conserved
among internally repeated domains 1–4.
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We have also demonstrated that synthetic membrane permeable
LSEAL is a potent inhibitor in two established models of calpain-
mediated cell death using primary rat cortical neurons and SH-
SY5Y neuroblastoma cells [8]. Analysis of the identiﬁed peptides
indicated their strong homology to calpastatin, the natural endog-
enous inhibitor of calpain activity. The amino acid sequence of cal-
pastatin contains repetitive peptide domains (see Fig. 1B), each of
which is capable of binding and inactivating one molecule of cal-
pain [9]. Our best compound, the LSEAL penta-peptide with the
strongest inhibitory activity against calpain, shows high homology
to conserved regions of calpastatin domains A and C. In our present
study we have shown by NMR that the LSEAL peptide indeed binds
to the calmodulin-like domain (CaMLD) of human calpain (see Sec-
tion 2) in vitro. We have also determined the ensemble of LSEAL
conformations bound to CaMLD and we have used the crystal
structure of porcine calpain small subunit calmodulin-like domain
(CaMLD-VI) complex with the peptide DIC19 derived from calpast-
atin domain C [10] to deﬁne by docking the possible positioning of
our penta-peptide inhibitor on the calpain surface.
2. Material and methods
2.1. Peptide synthesis
Peptide was synthesized using standard Fmoc chemistry and
puriﬁed using reverse-phase HPLC by Cell Essentials, Boston, MA.
The N-terminus was acetylated and the C-terminus was amidated.
2.2. Protein expression and puriﬁcation
CaMLD from human calpain I large subunit was prepared simi-
lar to previous studies [11]. Brieﬂy, the domain comprising of res-
idues 515-713 was PCR cloned from human calpain I cDNA (a
generous gift of Dr. Maki) using the primer pair (50-CTGCGCTTCCA-
TATGGAGAAGAGTGCT-30 and 50-CATGGCGGCCAAGCTTCTG-30).
The product was cut with NdeI and BamHI and pasted into a mod-
iﬁed pet30A to code for the proscribed amino acids plus the start-
ing methionine (CaMLD). This version of CaMLD was puriﬁed as
previously described using afﬁnity chromatography [11].
2.3. NMR spectroscopy
All NMR experiments were performed on Varian Inova 600 MHz
spectrometer equipped with inverse triple-resonance cold probe:
transferred nuclear Overhauser effect spectroscopy (NOESY) with400 ms mixing time at 288 K in the 50 mM KPi (50 mM NaCl,
0.5 mM CaCl2, pH 6.5) buffer at 20:1 ratio of the peptide
(1.6 mM) to CaMLD (0.08 mM) and 15N-HSQC on 0.1 mM 15N-la-
beled CaMLD in 20 mM Tris–Cl (50 mM NaCl, 0.1 mM EDTA,
0.5 mM CaCl2, 5 mM b-merc-enthanol pH 7.5) buffer at 313 K.
The resonance assignments of unlabeled peptide were made using
the conventional 2D-1H total correlation spectroscopy (TOCSY) and
NOESY spectra [12].
2.4. Structure calculations
The structures were calculated based on the hybrid distance
geometry-dynamical simulated annealing method [13] using the
X-PLOR program [14]. All the assigned NOEs were classiﬁed into
strong, medium, weak, and very weak categories corresponding to
interproton distance restraints of 1.8–2.7 Å (1.8–2.9 Å for NOEs
involving NH protons), 1.8–3.3 Å (1.8–3.5 Å for NOEs involving
NH protons), and 1.8–5.0 Å, and 1.8–6.0 Å, respectively [15,16].
Only structural useful intra-residue NOEs were included in the in-
tra-residue interproton distance restraints. The target function that
was minimized during simulated annealing (as well as during con-
ventional Powellminimization) comprises only quadratic harmonic
terms for covalent geometry, square-well quadratic potentials for
the experimental distance restraints [16]. Best structures from the
ensembles have been chosen based upon lowest Lennard–Jones po-
tential. The PROCHECK-NMR program was used for validation [17].
We have also reﬁned two major NMR-derived conformations of
LSEAL with time-averaged NOE distance restraints [18].
2.5. Modeling
We used the 3D-JIGSAW program [19] to build a three-dimen-
sional model for CaMLD based on its homology to the porcine small
subunit CaMLD-VI with known X-ray structure (1NX1). NMR-de-
rived LSEAL ensembles were docked into the CaMLD homolog of
CaMLD-VI/DIC19 binding site using Haddock2.0 [20].3. Results
3.1. NMR penta-peptide structure determination
To initially deﬁne the LSEAL/CaMLD interaction at the molecu-
lar level we ﬁrst ran 15N–1H heteronuclear single quantum correla-
tion (HSQC) experiment on 15N-labeled CaMLD of calpain.
Unfortunately, the resulting spectrum (see Fig. 2A) precluded us
from running the full scale triple-resonance experiments, needed
to determine the structure of the complex, or completing the
back-bone resonances assignment needed for peptide titration
experiments to characterize the binding surface of CaMLD.We only
accounted for approximately 140 amide peaks from the expected
200 corresponding to the number of amino acids in our CaMLD
vector. This is due to the relatively large size of CaMLD (24 kDa)
and its tendency to form homo-dimers, as has been shown by
size-exclusion chromatography and X-ray crystallography. We
did the titration of the unlabeled LSEAL to 15N-labeled CaMLD
(up to 1–10 ratio) and observed several HSQC peaks moving in a
concentration dependent manner, however the quality of the spec-
tra (data not shown) was poor.
Next, we decided to use an alternative approach, transferred
NOE (trNOE) experiments [21], which allowed us to characterize
the LSEAL penta-peptide in its bound to CaMLD form. This method
is especially well suited to characterize weak reversible interac-
tions [22] and is limited to systems where the free and bound
forms are in fast exchange. Brieﬂy, it is expected that unstructured
or only a partially folded peptide assumes a stable conformation
Fig. 2. (A) 15N-HSQC spectrum of calpain CaMLD. (B) TOCSY spectrum of free LSEAL amide region is shown to highlight assignments. (C) Transferred NOE evidence for LSEAL/
CaMLD interaction: all cross peaks of an amide ‘‘ﬁnger-print” region are trNOEs, there are no cross peaks in the control spectrum (not shown) of the free peptide in aqueous
solution.
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by appearance of additional peaks in its NOESY spectra (see
Fig. 2C). We conﬁrmed in vitro the direct interaction of LSEAL pep-
tide with CaMLD of calpain using this method. Furthermore, we
measured enough distance restraints (see Table 1) to calculate well
deﬁned structure of LSEAL bound to CaMLD. For ﬁve residue pep-
tide total of 59 NOEs, 15 of which not intra or sequential, is a pretty
good dataset. We have been surprised to see two possible LSEAL
conformations, both of which do not violate any of our experimen-
tal restraints. This observation would explain why attempts to
crystallize the CaMLD/LSEAL complex have not been successful
so far (Rodney Guttmann, personal communication) as endogenous
structural heterogeneity of the inhibitor in the binding pocket and
its ability to undergo fast exchange between free and bound states
would prevent the formation of crystals. However, one of the con-
formations has a higher population in our calculated ensembles
then the other. The ﬁrst conformation, heretofore referred to as
the twisted form, resembles one turn of the a-helix found in the
X-ray structure of the 19-residue peptide derivative of the natural
calpain inhibitor calpastatin bound to CaMLD-VI [10]. The second
conformation, heretofore referred to as the horseshoe form, is un-
ique and might represent a reasonable starting point for the designof a cyclo-peptide calpain inhibitor. Fig. 3A presents the backbone
superposition of 11 out 100 calculated structures with the lowest
Lennard–Jones potential (L–J) (below 7.5; these ensemble have
been deposited to the BMRB, entry assigned accession number is
20056). This ensemble is composed of 9 twisted and 2 horseshoe
conformers. When we lightened the limit of L–J a little to 6.5,
we have got 26 best structures, 16 of which are twisted and 10
are horseshoe (Fig. 3B, shown at 90 turn compared to Fig. 3A). Sta-
tistics for each ensemble are presented in Table 1. This population
distribution suggests that the second conformation is not a compu-
tational artifact of under-deﬁned experimental restraints. It rather
reﬂects the native state of the penta-peptide bound to CaMLD. To
investigate this idea further we have run calculations using either
of the two conformers as the starting point (instead of random
coiled template we used before). We have got 3 horseshoe con-
formers out of 38 best structures (L–J < 6.5) calculated from the
twisted conformer as the starting point and 10 horseshoe conform-
ers out of 20 best structures (L–J < 6.5) when started from the
horseshoe. These ﬁndings correlate well with our conclusion that
both conformers are possible in native complex, even though the
twisted form is more likely. We further reﬁned both our conform-
ers using time-averaging protocol [18]. The twisted conformer did
Table 1
Structural statistics of LSEAL bound ensembles.
Parameter Ensemblea Ensembleb
Distance restraints
All 59 59
Short range (|i  j|< = 1) 20 20
Medium range(1 < |i  j| < 5) 39 39
Long range (|i  j|> = 5) 0 0
Violations
NOE (>0.5 Å) 0 0
Vander-Waals Energy
7.57656 ± 0.8405 8.39891
± 0.62017
RMS deviation from idealized covalent
geometry
Bond (Å) 0.01067 ± 0.00016 0.01065 ± 0.00016
Angle () 0.70864 ± 0.09376 0.69709 ± 0.10418
Impropers () 0.32576 ± 0.10134 0.30055 ± 0.09871
RMSD (residues 1 to5)c
(a) All models
Average backbone RMSD to mean 1.23 ± 0.94 Å 1.12 ± 0.91 Å
Average backbone heavy atoms to
mean
2.30 ± 1.38 Å 2.13 ± 1.33 Å
(b) Twists
Average backbone RMSD to mean 0.38 ± 0.15 Å 0.32 ± 0.19 Å
Average backbone heavy atoms to
mean
0.99 ± 0.27 Å 0.95 ± 0.29 Å
(c) Horseshoe
Average backbone RMSD to mean 0.04 ± 0.05 Å 0.09 ± 0.06 Å
Average backbone heavy atoms to
mean
0.71 ± 0.22 Å 0.73 ± 0.22 Å
Ramachandran plotd
Residues in most favored regions 32.1% 48.5%
Residues in additional allowed
regions
52.6% 42.5%
Residues in generously allowed
regions
5.4% 9.1%
Residues in disallowed regions 0.0% 0.0%
a Ensemble of 26 structures.
b Ensemble of 11 structures.
c Calculated using MOLMOL [26].
d Calculated using PROCHECK-NMR [17].
Fig. 3. Ensembles of LSEAL bound to CaMLD: backbone superposition of: (A) 11 best
structures showing the combination of 9 twist and 2 horseshoe conformers, and (B)
26 best structures composed of 16 twist and 10 horseshoe conformers (rotated 90
in comparison to the point of view in (A). Backbone ribbon diagram of (C) twisted
(gray) and its time-average (dark gray) reﬁned and (D) horseshoe (gray) and its
time-average (dark gray) reﬁned conformers. The ﬁgure was generated by VMD-
XPLOR [24].
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be transformed to a more twisted form (Fig. 3C and D). However,
we do not believe that this protocol provides more reliable descrip-
tion of the native penta-peptide conformations because both re-
ﬁned structures have NOE violations which we do not see in our
original hybrid simulated annealing protocol.
3.2. Docking of the deﬁned penta-peptide conformations to the CaMLD
binding site
To predict the location where the LSEAL penta-peptide actually
binds, to ﬁnd out if both conformers can be ﬁtted to the same partFig. 4. Alignment of human CaMLD used in NMR LSEAL penta-peptide binding studies
residues overlap are underlined, additional homologous amino acids are marked by graof CaMLD surface and to explore how this high degree of structural
heterogeneity can be actually accommodated we decided to em-
ploy High Ambiguity Driven Docking protocol [20] and to use the
X-ray structure of the CaMLD-VI/DIC19 complex determined previ-
ously [10] as the starting point. To exploit this available X-ray
structure of calpain/calpastatin complex, we ﬁrst aligned the se-
quences of the porcine small subunit CaMLD-VI and the human
CaMLD vector employed for our NMR studies using SIM [23]. We
found 51% identity in 168 residue overlap (see Fig. 4). We used
the alignment to provide Haddock with arbitrary ambiguous re-
straints for placing our penta-peptide into the same binding pocket
where the LSSDF residues of the calpastatin-derived peptide DIC19
reside. Even though we understand that chosen restraints are
highly arbitrary and would favor the twisted conformer, without
this information docking cannot result in a converged structure
of the complex (data not shown). In addition to ambiguous re-
straints we provided our NOE data used in the structure calcula-
tions as an unambiguous restraints table during docking.
We used two NMR-derived ensembles containing 11 (9 twisted/
2 horseshoe conformers) and 26 (16 twisted/10 horseshoe) mem-
bers for CaMLD docking. We have got similar results in both cases:
a number of major complex clusters have been generated; both
twisted and horseshoe conformations can be found with approxi-
mately equal probability; on average, the horseshoe conformers
are better superimposed while the twisted conformers have a
higher degree of freedom and can slide within the binding site.
Here, we describe in more details the major cluster derived from
11-membered ensemble. Thousand structures are generated by ri-
gid body energy minimization. Two hundred best structures are
then subjected to semi ﬂexible simulated annealing and ﬁnallyand pig small subunit CaMLD-VI used for modeling. Identical amino acids in 168
y.
Fig. 5. (A) Superposition of 5 best CaMLD /LSEAL complex structures from the largest Haddock cluster. CaMLD is shown in different shades of cyan and LSEAL is shown in
orange and magenta for the twist and red for the horseshoe conformers. The complex is overlapped with X-ray structure of CaMLD-VI/DIC19 (PDB# 1NX1, shown in gray)
used to create CaMLD model and to deﬁne the starting point for docking. (B) The same ﬁve structures are rotated 90 counter-clockwise to give a better perspective of the
penta-peptide superposition. The docked twist (panels C and D, corresponding to orange and magenta backbone cartoons of panel B) and horseshoe (panel E) conformations
of the LSEAL peptide are presented within the CaMLD binding site; panel F presents the superposition of the structures shown in panels C–E. Interacting CaMLD residues are
highlighted in yellow. The ﬁgure was generated by PyMOL [25].
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tered based upon the pair wise backbone RMSD values using
3.0 Å cut off. The lowest energy cluster (E tot = 178.00) containing
34 structures satisﬁes the restraints and has the highest buried
surface area at the interface. Best ﬁve representative structures
from it are superimposed on Fig. 5A and B.
CaMLD binding site in our model is characterized by two deep
lipophilic pockets separated by W100. The walls of the binding site
are rich in hydrogen bond opportunities resulting from polar side-
chains and exposed backbone. Both terminal L residues of the pep-
tide twisted conformation make lipophilic interactions with the
pockets on either side of W100, where F33 and L36 are deﬁning the
ridge of the one side and the alkyl portions of K62, R104 and W100
deﬁning the other. E3 makes hydrogen bonding contacts with
R104 and central W100. The C-terminal carbonyls of L5 make hydro-
gen bonding contacts with H63 and K62. In the horseshoe conforma-
tion terminal L5 interacts with I59 while L1 comes close to the alkylportion of K62 on the same side of W100. E3 makes hydrogen bond-
ing contacts with R104. The C-terminal carbonyls of L5 make hydro-
gen bonding contacts with K62. Both conformations present very
feasible binding opportunities. Both conformations project S2 out
into solvent accessible space and neither projects side-chains into
the lipophilic pockets as deeply as the co-crystallized peptide. The
projection of S2 may be beneﬁcial as it would create ordering in the
waters around the side-chain.
4. Discussion
Several neurological diseases, including Parkinson’s and Hun-
tington’s, are characterized in part by increased calpain activity.
Cell death resulting from other degenerative conditions, such as
ischemic stroke or heart attack, is also known to be linked to in-
creased calpain activity. Recent work has shown potential for the
development of novel peptide-based compounds as therapeutic
140 L. Deshmukh et al. / FEBS Letters 583 (2009) 135–140agents to target calpain hyperactivity [8,27]. By using NMR spec-
troscopy to structurally characterize one such peptide, LSEAL,
bound to CaMLD, we have improved our understanding of the
interaction between LSEAL and calpain at the molecular level
which allows better assessment of the potential mechanism of cal-
pain action.
Having experimentally deﬁned structures of LSEAL penta-
peptide bound to human CaMLD allows us to suggest optional
linkers for synthesis of LSEAL cyclo-peptides which should have
improved pharmacological proﬁles combined with retained de-
sired calpain inhibitory abilities. In nature macromolecules, such
as cyclic peptide antibiotics for example, are often brought to a bio-
active conformation by ring formation. The increased rigidity plays
signiﬁcant role in improving their stability and resistance to degra-
dation. In summary, our data provides important clues of how to
increase LSEAL’s therapeutic potential by improving its resistance
to degradation and, thereby, to prolong its in vivo half-life neces-
sary for efﬁcient treatment of disease states in which calpain is
involved.
Acknowledgments
The work was supported in parts by grants from the University
of Connecticut Research Foundation to O.V. and American Heart
Association (0335233N) and NIH (NS047635) to R.P.G. We thank
Frank Delaglio and Dan Garrett for NMR and Alexandre Bovin for
modeling software.
References
[1] Goll, D.E., Thompson, V.F., Li, H., Wei, W. and Cong, J. (2003) The calpain
system. Physiol. Rev. 83, 731–801.
[2] Guttmann, R.P., Elce, J.S., Bell, P.D., Isbell, J.C. and Johnson, G.V. (1997)
Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J. Biol.
Chem. 272, 2005–2012.
[3] Dutt, P., Arthur, J.S., Croall, D.E. and Elce, J.S. (1998) M-calpain subunits remain
associated in the presence of calcium. FEBS Lett. 436, 367–371.
[4] Bartus, R.T., Elliott, P.J., Hayward, N.J., Dean, R.L., Harbeson, S., Straub, J.A., Li, Z.
and Powers, J.C. (1995) Calpain as a novel target for treating acute
neurodegenerative disorders. Neurol. Res. 17, 249–258.
[5] Wang, K.K. (2000) Calpain and caspase: can you tell the difference? by Kevin
K.W. Wang, vol. 23, pp. 20–26. Trends Neurosci 23, 59.
[6] Moldoveanu, T., Hosﬁeld, C.M., Lim, D., Elce, J.S., Jia, Z. and Davies, P.L. (2002) A
Ca(2+) switch aligns the active site of calpain. Cell 108, 649–660.
[7] Guttmann, R.P., Day 3rd, G.A., Wang, X. and Bottiggi, K.A. (2005) Identiﬁcation
of a novel calpain inhibitor using phage display. Biochem. Biophys. Res.
Commun. 333, 1087–1092.[8] McCollum, A.T., Jafarifar, F., Lynn, B.C., Agu, R.U., Stinchcomb, A.L., Wang, S.,
Chen, Q. and Guttmann, R.P. (2006) Inhibition of calpain-mediated cell death
by a novel peptide inhibitor. Exp. Neurol. 202, 506–513.
[9] Maki, M., Takano, E., Mori, H., Sato, A., Murachi, T. and Hatanaka, M. (1987) All
four internally repetitive domains of pig calpastatin possess inhibitory
activities against calpains I and II. FEBS Lett. 223, 174–180.
[10] Todd, B., Moore, D., Deivanayagam, C.C., Lin, G.D., Chattopadhyay, D., Maki, M.,
Wang, K.K. and Narayana, S.V. (2003) A structural model for the inhibition of
calpain by calpastatin: crystal structures of the native domain VI of calpain
and its complexes with calpastatin peptide and a small molecule inhibitor. J.
Mol. Biol. 328, 131–146.
[11] Yang, H.Q., Ma, H., Takano, E., Hatanaka, M. and Maki, M. (1994) Analysis of
calcium-dependent interaction between amino-terminal conserved region of
calpastatin functional domain and calmodulin-like domain of mu-calpain
large subunit. J. Biol. Chem. 269, 18977–18984.
[12] K. Wuthrich, NMR of Proteins and Nucleic Acids, John Wiley & Sons, New York
(1986).
[13] Nilges, M., Clore, G.M. and Gronenborn, A.M. (1988) Determination of three-
dimensional structures of proteins from interproton distance data by hybrid
distance geometry-dynamical simulated annealing calculations. FEBS Lett.
229, 317–324.
[14] A.T. Brunger, Yale University, New Haven, CT, (1993).
[15] Williamson, M.P., Havel, T.F. and Wuthrich, K. (1985) Solution conformation of
proteinase inhibitor IIA from bull seminal plasma by 1H nuclear magnetic
resonance and distance geometry. J. Mol. Biol. 182, 295–315.
[16] Clore, G.M., Nilges, M., Sukumaran, D.K., Brunger, A.T., Karplus, M. and
Gronenborn, A.M. (1986) The three-dimensional structure of a1-purothionin
in solution: combined use of nuclear magnetic resonance, distance geometry
and restrained molecular dynamics. EMBO J. 5, 2729–2735.
[17] Laskowski, R.A., MacArthur, M., Moss, D.S. and Thornton, J.M. (1993)
PROCHECK: a program to check the stereochemical quality of protein
structures. J. Appl. Crystallogr. 26, 283–291.
[18] Torda, A.E., Scheek, R.M. and van Gunsteren, W.F. (1990) Time-averaged
nuclear Overhauser effect distance restraints applied to tendamistat. J. Mol.
Biol. 214, 223–235.
[19] Bates, P.A., Kelley, L.A., MacCallum, R.M. and Sternberg, M.J. (2001)
Enhancement of protein modeling by human intervention in applying the
automatic programs 3D-JIGSAW and 3D-PSSM. Proteins 5 (Suppl.), 39–46.
[20] de Vries, S.J., van Dijk, A.D., Krzeminski, M., van Dijk, M., Thureau, A., Hsu, V.,
Wassenaar, T. and Bonvin, A.M. (2007) HADDOCK versus HADDOCK: new
features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69,
726–733.
[21] Clore, G.M. and Gronenborn, A.M. (1982) The two-dimensional transferred
nuclear Overhauser effect. J. Magn. Reson. 48, 402–417.
[22] Vaynberg, J. and Qin, J. (2006) Weak protein–protein interactions as probed by
NMR spectroscopy. Trend Biotechnol. 24, 22–27.
[23] Huang, X. and Miller, W. (1991) A time-efﬁcient, linear-space local similarity
algorithm. Adv. Appl. Math. 12, 337–357.
[24] Schwieters, C.D. and Clore, G.M. (2001) The VMD-XPLOR visualization package
for NMR structure reﬁnement. J. Magn. Reson. 149, 239–244.
[25] W.L. DeLano, DeLano Scientiﬁc LLC, Palo Alto, CA, USA, (2008).
[26] Koradi, R., Billeter, M. and Wuthrich, K. (1996) MOLMOL: a program for
display and analysis of macromolecular structures. J. Mol. Graph. 14 (51–55),
29–32.
[27] Guttmann, R.P., Day, G.A., 3rd, Wang, X. and Bottiggi, K.A. (2005) Identiﬁcation
of a novel calpain inhibitor using phage display. Biochem. Biophys. Res.
Commun. 333, 1087–1092.
